Tech Company Financing Transactions
Xellar Biosystems Funding Round
Xellar Biosystems closed a $50 million Series A funding round on 7/2/2026. Investors included private investors.
Transaction Overview
Company Name
Announced On
7/2/2026
Transaction Type
Venture Equity
Amount
$50,000,000
Round
Series A
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
500 Rutherford Ave
Boston, MA 02129
USA
Boston, MA 02129
USA
Phone
Undisclosed
Website
Email Address
Overview
Our platform combines our unique Organ-on-Chip technology, multicellular 3D disease model development, and Artificial Intelligence (AI) to provide spatiotemporal profiling and analysis of drug discovery, development, testing and treatment at a cellular level. Our microfluidic-based Organ-on-Chip technology recapitulates the multicellular microenvironment of the organ, incorporating vascularization, biomechanical structure and forces, and paracrine signaling experienced in vivo, providing an excellent in vitro model.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Xin Xie
Browse more venture capital transactions:
Prev: 7/2/2026: RenaissThera venture capital transaction
Next: 7/3/2026: Shortical venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records on this site are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs